You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: SEACOAST SCIENCE, INC. Topic: NIEHS
Project Summary This Small Business Technology Transfer Phase I project proposes the development and optimization of a commercially viable novel polymer based radiation dosimeter for wide spread deployment The radiation dosimeter proposed herein is a disruptive technology with a significant market Although many commercial radiation dosimeters measure individual radiation load dose quantificatio ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
A Clinical 3D Movement Analysis System for Assessing Lower Extremity Injury Risk and Recovery in AthletesSBC: BIONIKS Topic: NIAMS
DESCRIPTION provided by applicant The mission of Bioniks is to develop and commercialize accurate low cost movement analysis systems for clinicians ergonomists athletic trainers and other professionals interested in quantifying human movement Our initial focus is on developing computer enhancements for inexpensive D cameras like the Microsoft Kinect These enhancements surpass the accura ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemiaSBC: MICROFLUIDIC INNOVATIONS, LLC Topic: 102
DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health